

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings of claims in the application:


Listing of Claims:

1-70. (Cancel)

71. (Currently amended and withdrawn) A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound of any one of Claims ~~58~~ **and ~~59~~ 118 and 119.**

72-117 (Cancel)

118. (New) A compound having a formula



and their pharmaceutically acceptable salts, wherein

P² is selected from the group consisting of —C(O)—, —CH(OH)—, —C(O)O—, —OC(O)—, —NHC(O)NH—, —OC(O)NH—, —NHC(O)O—, —C(O)NH—, —NHC(O)—, and O(CH₂CH₂O)_q;


P³ is selected from the group consisting of C₂-C₆ alkynyl, C₁-C₆ haloalkyl, aryl, heteroaryl, -NHS(O)₂R², —C(O)OR² and carboxylic acid analogs, wherein R² is a member selected from the group consisting of hydrogen, unsubstituted C₁-C₄ alkyl, substituted C₁-C₄ alkyl, unsubstituted C₃-C₈ cycloalkyl, substituted C₃-C₈ cycloalkyl, unsubstituted aryl, substituted aryl, unsubstituted aryl C₁-C₄ alkyl, and substituted aryl C₁-C₄ alkyl;

the subscript q is 0 to 3;

L¹ is unsubstituted C₂-C₆ alkylene or substituted C₂-C₆ alkylene;

L² is unsubstituted C₂-C₁₂ alkylene or substituted C₂-C₁₂ alkylene.

119. (New) A compound having a formula (I):



(I)

and their pharmaceutically acceptable salts, wherein

R^1 is a member selected from the group consisting of aryl and heteroaryl;

P^1 is a primary pharmacophore selected from the group consisting of —

NHC(O)NH—, —OC(O)NH—, —NHC(O)O—, —CH₂C(O)NH—, —C(O)NH— and —NHC(O)—;

P^2 is a secondary pharmacophore selected from the group consisting of —C(O)—,

—CH(OH)—, —O(CH₂CH₂O)_q—, —C(O)O—, —OC(O)—, —NHC(O)NH—, —OC(O)NH—, —NHC(O)O—, —C(O)NH— and —NHC(O)—;

P^3 is a tertiary pharmacophore selected from the group consisting of C₂-C₆

alkynyl, C₁-C₆ haloalkyl, aryl, heteroaryl, —C(O)NHR¹, —C(O)NHS(O)₂R¹, —NHS(O)₂R²,

—C(O)OR² and carboxylic acid analogs, wherein R² is a member selected from the group

consisting of hydrogen, unsubstituted C₁-C₄ alkyl, substituted C₁-C₄ alkyl, unsubstituted C₃-C₈

cycloalkyl, substituted C₃-C₈ cycloalkyl, unsubstituted aryl, substituted aryl, unsubstituted aryl

C₁-C₄ alkyl, and substituted aryl C₁-C₄ alkyl;

the subscripts n and m are each independently 0 or 1, and at least one of n or m is

1, and the subscript q is 0 to 3;

L^1 is a first linker selected from the group consisting of unsubstituted C₂-C₆

alkylene, substituted C₂-C₆ alkylene, unsubstituted C₃-C₆ cycloalkylene, substituted C₃-C₆

cycloalkylene, unsubstituted arylene, substituted arylene, unsubstituted heteroarylene, and

substituted heteroarylene; and

L^2 is a second linker selected from the group consisting of unsubstituted C₂-C₁₂

alkylene, substituted C₂-C₁₂ alkylene, unsubstituted arylene, substituted arylene, and

combinations thereof.

120. (New) The compound according to any one of claims 118 and 119,

wherein P^3 is —C(O)OR² or a carboxylic acid analog, wherein R² is selected from the group

consisting of hydrogen, unsubstituted C₁-C₄ alkyl, substituted C₁-C₄ alkyl, unsubstituted C₃-C₈ cycloalkyl, and substituted C₃-C₈ cycloalkyl.

121. (New) The compound according to any one of Claims 118 and 119, wherein P³ is -C(O)OR² or a carboxylic acid analog, wherein R² is selected from the group consisting of hydrogen, methyl, and ethyl.

122. (New) The compound of Claim 119, wherein R¹ is selected from the group consisting of phenyl and naphthyl.

123. (New) The compound of Claim 119, wherein R¹ is phenyl.

124. (New) The compound Claim 119, wherein R¹ is phenyl, wherein the phenyl is either unsubstituted or substituted with from one to three substituents selected from the group consisting of halogen, lower alkyl, lower halo alkyl, lower alkoxy, C₃-C₅ cycloalkyl, and cyano.

125. (New) The compound of Claim 119, wherein P¹ is selected from the group consisting of -NHC(O)CH-, -OC(O)NH-, and -NHC(O)O-.

126. (New) The compound of Claim 119, wherein P¹ is -NHC(O)CH-.

127. (New) The compound of Claim 119, wherein L¹ is an alkylene of from 2 to 4 carbon atoms,

P² is not present; and

L² is an alkylene of from 2 to 8 carbon atoms.

128. (New) The compound of Claim 119, wherein P¹ is selected from the group consisting of -NHC(O)NH-, -OC(O)NH- and -NHC(O)O-;

n is 0;





m is 1;






L¹ is selected from the group consisting of unsubstituted C₂-C₆ alkylene, unsubstituted C₃-C₆cycloalkylene, substituted C₃-C₆cycloalkylene, unsubstituted arylene, and substituted arylene;

L^2 is selected from the group consisting of unsubstituted C_2 - C_6 alkylene and substituted C_2 - C_6 alkylene; and


P^3 is selected from the group consisting of C_2 - C_6 alkynyl, C_1 - C_6 haloalkyl, aryl, heteroaryl, $-C(O)NHR^2$, $-C(O)NHS(O)_2R^2$, $-NHS(O)_2R^2$, $-C(O)OR^2$, and carboxylic acid analogs, wherein R^2 is a member selected from the group consisting of hydrogen, unsubstituted C_1 - C_4 alkyl, substituted C_1 - C_4 alkyl, unsubstituted C_3 - C_8 cycloalkyl, substituted C_3 - C_8 cycloalkyl, unsubstituted aryl, substituted aryl, unsubstituted aryl C_1 - C_4 alkyl, and substituted aryl C_1 - C_4 alkyl.

129. (New) A compound having the formula selected from the group consisting of:







92




93




94




95




96




97




98




99




100




101




102







103




104







111




112




113




114




115




116




117




118




119




120




121




122




123




124




125




126




127




128




129




130




131




132




133




134




135




136




137




138




139




140




141




142




143




144




145




146




147




148




149




150










151



152





160 wherein Z is O or NH;

161 R³ is alkyl;


162 n1 is 1, 2, 3, 4, 6, 7, 9, 10, or 11;

163 n2 is 1, 2, 3, or 4;


164 n3 is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10;

165 and their pharmaceutically acceptable salts.

166 **130.** (New) A compound having the formula:



131. (New) A compound having a formula



and their pharmaceutically acceptable salts, wherein

P³ is selected from the group consisting of C₂-C₆ alkynyl, C₁-C₆ haloalkyl, aryl, heteroaryl, -NHS(O)₂R², -C(O)OR² and carboxylic acid analogs, wherein R² is a member selected from the group consisting of hydrogen, unsubstituted C₁-C₄ alkyl, substituted C₁-C₄ alkyl, unsubstituted C₃-C₈ cycloalkyl, substituted C₃-C₈ cycloalkyl, unsubstituted aryl, substituted aryl, unsubstituted aryl C₁-C₄ alkyl, and substituted aryl C₁-C₄ alkyl;

the subscript m is 1;

L¹ is unsubstituted C₃-C₄ alkylene or substituted C₃-C₄ alkylene;

L² is unsubstituted C₈ alkylene or substituted C₈ alkylene.

132. (New) A compound having the formula:

